Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))

Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)) Publisher Pubmed

Khalighfard S¹ ; Alizadeh AM^{2, 3} ; Poorkhani A⁴ ; Motahari M⁵ ; Tahmasebifar A⁵ ; Omranipour R² ; Keshavarz P⁶ ; Haddad P¹

Show Affiliations

1. Radiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2. Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
3. Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
5. Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
6. Department of Radiology, Tbilisi State Medical University (TSMU), Tbilisi, Georgia

Source: European Journal of Pharmacology Published:2024

Abstract

This article has been retracted at the request of Editor-in-Chief. The authors requested to publish a corrigendum to rectify mistakenly used images in Figures 1 and 4, which contain identical parts to the images in Figure 1 of another article by the same author group (Khori et al., 2018 Peptide, 107, 54–60, 10.1016/j.peptides.2018.07.007). The editor found more concerns about the integrity of the images shown in Figures 4, based on the in-house image analysis and reported suspected image duplications. Furthermore, in-house image analysis revealed that, in Figure 6, the Western blot subfigures for BCL2 (ADR + Cyclo and ADR + Cyclo + Tax) appear identical to these of Caspase 3 (Control and TAM), but the figure has been rotated 180°. The Editor asked the authors for an explaination, but a satisfactory answer was not provided. Due to the above concerns, the Editor decided to retract the paper. © 2024 Elsevier B.V.

Style	Citing Format
MLA	Khalighfard S, et al.. "Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))." European Journal of Pharmacology, vol. 969, no. , 2024, pp. -.
APA	Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, Keshavarz P, Haddad P (2024). Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)). European Journal of Pharmacology, 969(), -.
Chicago	Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, Keshavarz P, Haddad P. "Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))." European Journal of Pharmacology 969, no. (2024): -.
Harvard	Khalighfard S et al. (2024) 'Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))', European Journal of Pharmacology, 969(), pp. -.
Vancouver	Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, et al.. Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)). European Journal of Pharmacology. 2024;969():-.
BibTex	@article{ author = {Khalighfard S and Alizadeh AM and Poorkhani A and Motahari M and Tahmasebifar A and Omranipour R and Keshavarz P and Haddad P}, title = {Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))}, journal = {European Journal of Pharmacology}, volume = {969}, number = {}, pages = {-}, year = {2024} }
RIS	TY - JOUR AU - Khalighfard S AU - Alizadeh AM AU - Poorkhani A AU - Motahari M AU - Tahmasebifar A AU - Omranipour R AU - Keshavarz P AU - Haddad P TI - Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)) JO - European Journal of Pharmacology VL - 969 IS - SP - EP - PY - 2024 ER -

Style

Citing Format

MLA

Khalighfard S, et al.. "Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))." European Journal of Pharmacology, vol. 969, no. , 2024, pp. -.

APA

Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, Keshavarz P, Haddad P (2024). Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)). European Journal of Pharmacology, 969(), -.

Chicago

Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, Keshavarz P, Haddad P. "Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))." European Journal of Pharmacology 969, no. (2024): -.

Harvard

Khalighfard S et al. (2024) 'Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))', European Journal of Pharmacology, 969(), pp. -.

Vancouver

Khalighfard S, Alizadeh AM, Poorkhani A, Motahari M, Tahmasebifar A, Omranipour R, et al.. Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)). European Journal of Pharmacology. 2024;969():-.

BibTex

@article{ author = {Khalighfard S and Alizadeh AM and Poorkhani A and Motahari M and Tahmasebifar A and Omranipour R and Keshavarz P and Haddad P}, title = {Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))}, journal = {European Journal of Pharmacology}, volume = {969}, number = {}, pages = {-}, year = {2024} }

RIS

TY - JOUR
AU - Khalighfard S
AU - Alizadeh AM
AU - Poorkhani A
AU - Motahari M
AU - Tahmasebifar A
AU - Omranipour R
AU - Keshavarz P
AU - Haddad P
TI - Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605))
JO - European Journal of Pharmacology
VL - 969
IS -
SP -
EP -
PY - 2024
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract